Boston Scientific price target raised to $82 from $72 at Wells Fargo

Wells Fargo raised the firm’s price target on Boston Scientific to $82 from $72 and keeps an Overweight rating on the shares. The firm notes Boston Scientific reported Q1 revenue/EPS ahead of Street and raised 2024 revenue guidance by 250bps at the midpoint to 10%-12%. With earlier-than-expected U.S. Farapulse launch and the raised 2024 guide, Wells believes there is upside to Boston’s 2024-2026 LRP of 8%-10%.